Federated Hermes’s Zevra Therapeutics ZVRA Stock Holding History

Federated Hermes’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$776K	Buy	54,111 +11,916	+28%	+$132K	﹤0.01%	1213
2026 Q1	$393K	Buy	42,195 +18,742	+80%	+$169K	﹤0.01%	1360
2025 Q4	$210K	Buy	23,453 +3,539	+18%	+$33.5K	﹤0.01%	1492
2025 Q3	$189K	Buy	19,914 +19,090	+2,317%	+$191K	﹤0.01%	1515
2025 Q2	$7.26K	Buy	+824	New	+$6.69K	﹤0.01%	1856
2017 Q3	–	Sell	-10,000	Closed	-$640K	–	2202
2017 Q2	$640K	Hold	10,000	–	–	﹤0.01%	1331
2017 Q1	$784K	Sell	10,000 -2,500	-20%	-$152K	﹤0.01%	1242
2016 Q4	$590K	Hold	12,500	–	–	﹤0.01%	1267
2016 Q3	$898K	Hold	12,500	–	–	﹤0.01%	1127
2016 Q2	$796K	Hold	12,500	–	–	﹤0.01%	1156
2016 Q1	$2.9M	Hold	12,500	–	–	0.01%	696
2015 Q4	$3.97M	Hold	12,500	–	–	0.01%	634
2015 Q3	$3.88M	Buy	12,500 +1,250	+11%	+$383K	0.01%	643
2015 Q2	$3.31M	Buy	+11,250	New	+$2.45M	0.01%	744

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Federated Hermes's ZVRA Position: Q2 2026 in Review

Federated Hermes increased its Zevra Therapeutics (ZVRA) stake by 28% in Q2 2026, buying an estimated $132K and bringing the position to 54,111 shares worth $776K. The position accounts for ﹤0.01% of the portfolio, ranked #1213.

Federated Hermes first reported a position in ZVRA in Q2 2015 and has held it in 14 quarters since. The position peaked at $3.97M in Q4 2015. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Federated Hermes held 54,111 shares of Zevra Therapeutics worth $776K as of Q2 2026.
Federated Hermes bought 11,916 Zevra Therapeutics shares in Q2 2026, an estimated $132K.
Zevra Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1213 holding.
Federated Hermes first reported a position in Zevra Therapeutics in Q2 2015 and has held it in 14 quarters since.
Federated Hermes's Zevra Therapeutics position peaked at $3.97M in Q4 2015.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.